Drug Manufacturing

Roche, Genentech sign license deal with Kiniksa for vixarelimab

Kiniksa Pharmaceuticals has entered into a global license agreement with Roche and its subsidiary, Genentech, for the development and commercialisation of an investigational fully human monoclonal antibody, vixarelimab.

ViiV Healthcare, Medicines Patent Pool partner to expand HIV drug access

ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).

Procaps Group signs agreement to buy Grupo Somar

Procaps Group, an integrated LatAm healthcare and pharmaceutical conglomerate, has signed a definitive agreement to buy Grupo Somar, which includes Grupo Farmacéutico Somar and Química y Farmacia and, Gelcaps and associated entities from Advent International, a private equity investor.

Artax Biopharma to develop oral small molecule immunomodulating agent

Artax Biopharma is set to develop its first oral small molecule immunomodulating agent, AX-158, after it closed a $26m financing round.

Asahi Kasei Medical agrees to buy Bionova Scientific

Asahi Kasei Medical’s US subsidiary has signed an agreement to acquire Bionova Scientific for an undisclosed amount.

Clovis Oncology, Evergreen partner for actinium-225-labeled FAP-2286

Clovis Oncology and Evergreen Theragnostics have initiated a development, manufacturing, and services agreement for actinium-225-labeled-FAP-2286 (225Ac-FAP-2286).

Yantai Luye, Chengdu Biostar partner to market anticancer drug in mainland China

Luye Pharma Group’s wholly owned subsidiary Yantai Luye Drugs Trading has collaborated with Beijing Biostar Pharmaceuticals’ subsidiary Chengdu Biostar Pharmaceuticals for marketing anticancer drug, Utidelone Injection, in Chinese mainland.

Alvotech, BiosanaPharma partner to develop biosimilar for Xolair

Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).

Ocugen to buy Liminal’s vaccine manufacturing facility in Canada

US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.